Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun Pharma, Shanghai Pharma Deny Interest In Stada

Executive Summary

Fosun Pharma and Shanghai Pharma have both officially denied their involvement in any bidding battle for German company Stada, although both Chinese firms make no secret of their international expansion ambitions and have been active deal makers in the past.

You may also be interested in...



Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals

Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.

Hengrui Pursues Innovation Through New $100m US Spinoff

China’s Jiangsu Hengrui Medicine is accelerating its move towards innovation by increasing investment and partnerships, as part of a strategy to shift its focus away from its traditional generic business. It is now providing substantial funding to a new US-based spinoff aiming to develop oncology biologics and immunotherapies and to act as an innovation bridge between the US and China.

Fosun Pitches For India’s Gland

China’s Shanghai Fosun Pharma has confirmed its interest in the Indian injectables firm Gland Pharma, underscoring how differentiated niche plays continue to attract buyer interest.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel